Stable Biodegradable Polymers for Delivery of Both Polar and Non-Polar Drugs. Phase I
Final rept. 15 Mar-14 Sep 1996
CAMBRIDGE SCIENTIFIC INC BELMONT MA
Pagination or Media Count:
The objective of this project is to develop improved dose forms for the delivery of pain management agents. Given a military scenario where rapid deployment of Special Operations Forces demands effective medical resources, the need for therapeutic pain management tools is obvious. Pain relief is critical in maintaining the ability of the field soldier to defend and protect himself particularly in cases where mobilization is not imminent. Our development work on a pain management system, of which a hydromorphoneHM polylactide-co-glycolide PLGA delivery system is a part, addresses battlefield treatment with respect to personnel maintenance. A long acting HMPLGA implant, easily implanted via a loaded trocar, could provide systemic relief from pain at the time of injury. Phase I work included in vitro and in vivo mice testing of four HMPLGA matrices, HM at 25 and 50 loading in each of two PLGAs 8515 and 5050. In vitro release data and mouse tail flick data permitted selection of a system for further development - a 5050 PLGA containing 25 HM. Data support its use as a 10 day pain management system for combat casualty care.
- Medicine and Medical Research